CA3131729A1 - Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof - Google Patents

Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof Download PDF

Info

Publication number
CA3131729A1
CA3131729A1 CA3131729A CA3131729A CA3131729A1 CA 3131729 A1 CA3131729 A1 CA 3131729A1 CA 3131729 A CA3131729 A CA 3131729A CA 3131729 A CA3131729 A CA 3131729A CA 3131729 A1 CA3131729 A1 CA 3131729A1
Authority
CA
Canada
Prior art keywords
cyfra21
areg
f1t3l
clec2c
erbb4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3131729A
Other languages
English (en)
French (fr)
Inventor
Ana Carmen Martin Rodriguez
Rosa Perez Palacios
Rocio Arroyo Arranz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Marker Discovery SL AMADIX
Original Assignee
Advanced Marker Discovery SL AMADIX
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Marker Discovery SL AMADIX filed Critical Advanced Marker Discovery SL AMADIX
Publication of CA3131729A1 publication Critical patent/CA3131729A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3131729A 2019-03-01 2020-02-28 Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof Pending CA3131729A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19382157.6 2019-03-01
EP19382157 2019-03-01
EP19382156 2019-03-01
EP19382156.8 2019-03-01
PCT/EP2020/055277 WO2020178172A1 (en) 2019-03-01 2020-02-28 Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof

Publications (1)

Publication Number Publication Date
CA3131729A1 true CA3131729A1 (en) 2020-09-10

Family

ID=69631636

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3131729A Pending CA3131729A1 (en) 2019-03-01 2020-02-28 Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof

Country Status (10)

Country Link
US (1) US20220276249A1 (https=)
EP (1) EP3931571B1 (https=)
JP (2) JP2022522803A (https=)
KR (1) KR102769007B1 (https=)
CN (1) CN113785199B (https=)
AU (1) AU2020230963B2 (https=)
CA (1) CA3131729A1 (https=)
ES (1) ES2952139T3 (https=)
MX (1) MX2021010451A (https=)
WO (1) WO2020178172A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952139T3 (es) * 2019-03-01 2023-10-27 Advanced Marker Discovery S L Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo
WO2021185982A1 (en) * 2020-03-19 2021-09-23 Advanced Marker Discovery S.l. Protein signature for screening general population for colorectal cancer and/or pre-cancerous stage thereof
CA3202255A1 (en) 2020-12-21 2022-06-30 Hayley WARSINSKE Markers for the early detection of colon cell proliferative disorders
KR102900859B1 (ko) * 2021-12-31 2025-12-17 주식회사 이노제닉스 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005014386D1 (de) * 2004-12-23 2009-06-18 Roche Diagnostics Gmbh Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
CN101896817A (zh) * 2007-12-10 2010-11-24 霍夫曼-拉罗奇有限公司 用于结直肠癌的标记物组
CN103140760B (zh) * 2010-07-14 2016-01-27 联邦科学与工业研究组织 结肠直肠癌的诊断
US20140220006A1 (en) * 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Lung cancer biomarkers
US20160291025A1 (en) * 2013-09-18 2016-10-06 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
JP6339399B2 (ja) * 2014-03-28 2018-06-06 学校法人北里研究所 卵巣明細胞腺癌細胞の検出方法、卵巣明細胞腺癌診断薬、卵巣明細胞腺癌診断用プライマー、卵巣明細胞腺癌診断用キット、及び卵巣明細胞腺癌診断用プローブ
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
JP2018136122A (ja) * 2015-05-29 2018-08-30 国立研究開発法人国立がん研究センター 膵がんを診断するための血漿バイオマーカーパネル
US20180160885A1 (en) * 2016-12-13 2018-06-14 Prosper Abitbol Endoscopy based medical devices, methods, and innovations
KR102018205B1 (ko) * 2017-07-24 2019-09-05 (주) 바이오인프라생명과학 대장암 진단용 조성물 및 상기 조성물을 이용한 대장암 진단 방법
US10968583B2 (en) * 2017-07-26 2021-04-06 David E. Lambert Reflective road marker
ES2952139T3 (es) * 2019-03-01 2023-10-27 Advanced Marker Discovery S L Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo
WO2021185982A1 (en) * 2020-03-19 2021-09-23 Advanced Marker Discovery S.l. Protein signature for screening general population for colorectal cancer and/or pre-cancerous stage thereof

Also Published As

Publication number Publication date
US20220276249A1 (en) 2022-09-01
AU2020230963A1 (en) 2021-09-30
CN113785199A (zh) 2021-12-10
EP3931571B1 (en) 2023-06-07
JP2022522803A (ja) 2022-04-20
BR112021017248A2 (pt) 2021-11-09
EP3931571C0 (en) 2023-06-07
KR102769007B1 (ko) 2025-02-14
ES2952139T3 (es) 2023-10-27
JP2025038186A (ja) 2025-03-18
WO2020178172A1 (en) 2020-09-10
EP3931571A1 (en) 2022-01-05
KR20210134946A (ko) 2021-11-11
AU2020230963B2 (en) 2026-03-12
MX2021010451A (es) 2021-12-10
CN113785199B (zh) 2024-02-09

Similar Documents

Publication Publication Date Title
US10408839B2 (en) Biomarker panel for diagnosing cancer
AU2020230963B2 (en) Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof
US11193935B2 (en) Compositions, methods and kits for diagnosis of lung cancer
JP2025114736A (ja) 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療の方法並びにそのキット
JP2017133831A (ja) 大腸がんの転移検出方法
JP2018136122A (ja) 膵がんを診断するための血漿バイオマーカーパネル
US20170168058A1 (en) Compositions, methods and kits for diagnosis of lung cancer
CN118465282A (zh) 预测结直肠癌肝转移的生物标志物组合、试剂盒、系统及其应用
Du et al. Analysis of variation of serum CEA, SCC, CYFRA21-1 in patients with lung cancer and their diagnostic value with EBUS-TBNA
CN116256521B (zh) 一种用于肠癌诊断的粪便外泌体蛋白的标志物及其应用
US20230204584A1 (en) Protein signature for screening general population for colorectal cancer and/or pre-cancerous stage thereof
CN120210363A (zh) 用于诊断晚期鼻咽癌的生物标志物及其应用
EP4357782A1 (en) Protein biomarker panel for the diagnosis of colorectal cancer
RU2830580C2 (ru) Белковая сигнатура для диагностики колоректального рака или его предраковой стадии
BR112021017248B1 (pt) Método in vitro para o diagnóstico de câncer colorretal e/ou um seu estágio pré- canceroso, usos in vitro da combinação de [flt3l e cyfra21-1] e da combinação de da combinação de [flt3l e cyfra21-1 e areg], ou [flt3l e cyfra21-1 e areg e erbb4], ou {flt3l e cyfra21-1 e areg e clec2c] em uma amostra biológica obtida do paciente,e uso de um kit de partes
WO2026068798A1 (en) Sox9 for assessing colorectal cancer (crc) or a precancerous condition thereof
Al-Athwary et al. A tumor-associated autoantibody panel for early detection of breast cancer in Sana’a, Yemen
CN119804865A (zh) 细胞外囊泡蛋白质作为诊断腹主动脉瘤的生物标志物及应用
CN117169504A (zh) 用于胃癌相关参数检测的生物标志物及相关预测系统及应用
US20160060708A1 (en) Method for detecting the risk of early gastric cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240115

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250204

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250602

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250602

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250602

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250602

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250815

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250903

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251028